Literature DB >> 23559322

[Adjuvant stereotactic low energy radiation therapy of exudative age-dependent macular degeneration (Oraya system)].

S Pollithy1, N Celik, H Höh, S Dithmar.   

Abstract

With respect to the increasing number of patients and the risk and burden for patients caused by injections, a reduction in the number and frequency of injections with vascular endothelial growth factor (VEGF) inhibitors in exudative age-related macular degeneration (ARMD) is desirable. Stereotactic low-voltage x-ray irradiation seems to be a promising approach. For this purpose the Oraya system is available and has shown positive results in initial studies. Pending presentation of phase II and III study data this adjuvant irradiation should only be used in clinical trials.

Entities:  

Mesh:

Year:  2013        PMID: 23559322     DOI: 10.1007/s00347-012-2741-6

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  17 in total

1.  A prospective, randomized, double-masked trial on radiation therapy for neovascular age-related macular degeneration (RAD Study). Radiation Therapy for Age-related Macular Degeneration.

Authors: 
Journal:  Ophthalmology       Date:  1999-12       Impact factor: 12.079

2.  Twelve-month safety and visual acuity results from a feasibility study of intraocular, epiretinal radiation therapy for the treatment of subfoveal CNV secondary to AMD.

Authors:  Marcos P Avila; Michel Eid Farah; Arturo Santos; Ziya Kapran; João Paulo Duprat; Benjamin W Woodward; Jeffrey Nau
Journal:  Retina       Date:  2009-02       Impact factor: 4.256

Review 3.  Radiation treatment for age-related macular degeneration.

Authors:  Ruwan A Silva; Andrew A Moshfeghi; Peter K Kaiser; Rishi P Singh; Darius M Moshfeghi
Journal:  Semin Ophthalmol       Date:  2011-05       Impact factor: 1.975

4.  [Radiotherapy for choroidal neovascularization (CNV) in age-related macular degeneration (AMD)].

Authors:  A M Thölen; A Meister; P P Bernasconi; E P Messmer
Journal:  Klin Monbl Augenheilkd       Date:  2000-02       Impact factor: 0.700

5.  Treatment of age-related subfoveal neovascular membranes by teletherapy: a pilot study.

Authors:  U Chakravarthy; R F Houston; D B Archer
Journal:  Br J Ophthalmol       Date:  1993-05       Impact factor: 4.638

6.  Randomized trial of radiation for age-related macular degeneration.

Authors:  D H Char; A I Irvine; M D Posner; J Quivey; T L Phillips; S Kroll
Journal:  Am J Ophthalmol       Date:  1999-05       Impact factor: 5.258

7.  The age-related macular degeneration radiotherapy trial (AMDRT): one year results from a pilot study.

Authors:  Dennis M Marcus; Ellen Peskin; Maureen Maguire; David Weissgold; Judith Alexander; Stuart Fine; David Followill
Journal:  Am J Ophthalmol       Date:  2004-11       Impact factor: 5.258

8.  External beam irradiation of subfoveal choroidal neovascularization complicating age-related macular degeneration: one-year results of a prospective, double-masked, randomized clinical trial.

Authors:  D M Marcus; W Sheils; M H Johnson; S B McIntosh; D B Leibach; A Maguire; J Alexander; C N Samy
Journal:  Arch Ophthalmol       Date:  2001-02

9.  24-Gy low-voltage x-ray irradiation with ranibizumab therapy for neovascular AMD: 6-month safety and functional outcomes.

Authors:  Virgilio Morales Canton; Hugo Quiroz-Mercado; Raul Velez-Montoya; Miriam J Lopez-Miranda; Andrew A Moshfeghi; Eugene M Shusterman; Peter K Kaiser; Steven R Sanislo; Michael Gertner; Darius M Moshfeghi
Journal:  Ophthalmic Surg Lasers Imaging       Date:  2012 Jan-Feb

10.  Radiation therapy for neovascular age-related macular degeneration.

Authors:  Robert Petrarca; Timothy L Jackson
Journal:  Clin Ophthalmol       Date:  2011-01-10
View more
  1 in total

Review 1.  [Adjuvant radiotherapy during anti-VEGF in neovascular age-related macular degeneration].

Authors:  P Rating; M-A Freimuth; M Stuschke; N Bornfeld
Journal:  Ophthalmologe       Date:  2017-04       Impact factor: 1.059

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.